PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Pooled semaglutide trials show 16% lower kidney composite risk

semaglutideGLP-1 receptor agonistchronic kidney diseasetype 2 diabetesobesityatherosclerotic cardiovascular diseaseSELECTFLOWSOULpooled analysiskidney outcomeseGFRSGLT2 inhibitornephrology Nephrology

Background Information

Semaglutide offers potential kidney benefits in cardio-metabolic diseases.

Understanding the renal impact of semaglutide can guide dosing and management in patients with cardio-kidney-metabolic diseases. Pooled data from 30,787 participants showed significant improvement in kidney outcomes with semaglutide treatment. Although encouraging, individual patient response may vary. The analysis informs potential semaglutide benefits but warrants clinical correlation. Semaglutide shows promise in improving kidney outcomes in cardio-kidney-metabolic diseases.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Mann JFE, Badve SV, Baeres FMM, Belmar N, Brown-Frandsen K, Buse JB, Colhoun HM, Deanfield JE, Engelmann MDM, Hovingh GK, Idorn T, Lincoff AM, Lingvay I, Mahaffey KW, McGuire DK, Pratley RE, Rasmussen S, Rossing P, Sattar N, Tuttle KR, Perkovic V

Citation: Mann JFE, Badve SV, Baeres FMM, et al. Effect of semaglutide on kidney outcomes in the SELECT, FLOW, and SOUL trials: a prespecified pooled analysis. The lancet. Diabetes & endocrinology. 2026;14(10):818-830. doi:10.1016/S2213-8587(26)00134-8

Article Links: PubMed · Journal / DOI

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.